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Coccidioidomycosis, a systemic fungal infection, affects Americans living in the
Southwest. We evaluated the cost-effectiveness of a potential vaccine against
Coccidioides immitis. Using a decision model we developed, we estimate that
among children, vaccination would save 1.9 quality-adjusted life days (QALD)
and $33 per person. Among adults, screening followed by vaccination would
save 0.5 QALD per person and cost $62,000 per quality adjusted life year
gained over no vaccination. If the birth cohort in highly endemic counties of
California and Arizona were immunized in 2001, 11 deaths would be averted
and $3 million would be saved (in net present value) over the lifetime of these
infants. Vaccination of adults to prevent disseminated coccidioidomycosis
would provide a modest health benefit similar in magnitude to other vaccines
but would increase net expenditures. Vaccination of children in highly endemic
regions would provide a larger health benefit and would reduce total health
care expenditures.
Coccidioides immitis, an infectious fungus, grows in the
arid soil of the Central Valley of California, southern Ari-
zona, and parts of Nevada, New Mexico, Utah, and Texas, as
well as northern Mexico and parts of Central and South
America. Regions endemic for  C. immitis are home to
approximately 20% of the U.S. population; an estimated 5
million persons live in the areas of highest endemicity (Fig-
ure 1) (1-3). Humans are infected by inhaling dust contain-
ing C. immitis arthroconidia. Dust storms (4,5) and activities
associated with heavy dust exposure such as agricultural
labor (6), excavating archeologic ruins (7), and military com-
bat training (8,9) increase infection rates, total infectious
load, and the proportion of symptomatic cases. Infection
rates, as reflected by positive skin tests, have decreased
since the 1940s and 1950s from as high as 8% per month to
approximately 2% to 3% per year in highly endemic regions.
This decrease is likely the result of reduced dust exposure
attributable to lifestyle changes and urbanization. However,
population growth in endemic regions has been steady and is
projected to increase. 
Recent epidemics in California and Arizona highlight
the continuing public health threat and costs of coccidioido-
mycosis (10,11) and have led to efforts to develop a vaccine.
An economic analysis of the 7,130 cases from 1991 to 1993 in
California’s Kern County demonstrated a cost to that county
of $56 million (12). Because the U.S. training post for desert
warfare is located in the Mojave Desert, an area endemic for
C. immitis, a vaccine is a military as well as a civilian prior-
ity. A killed whole spherule vaccine that showed promise in
animal trials was not well tolerated in humans (13). Current
efforts of the Valley Fever Vaccine Project, a consortium of
researchers funded primarily by the California Healthcare
Foundation and the California Department of Health Ser-
vices, focus on a number of antigens successful in mice mod-
els that may form the basis of a subunit vaccine (G.
Rutherford, pers. comm.).
Despite the potential clinical value of a vaccine, the only
study of the cost-effectiveness of a vaccination program was
an Institute of Medicine (IOM) analysis for the purposes of
setting priorities in vaccine development (14). The IOM con-
cluded that vaccine development would cost more than
$100,000 per quality-adjusted life year (QALY) gained, but
included vaccine development costs and used a very simpli-
fied model. If the vaccine would not be cost-effective, current
development efforts might be in vain. We present the results
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Figure 1. Areas in the United States endemic for Coccidioides immi-
tis. Cross-hatching indicates the heavily disease-endemic area; sin-
gle hatching indicates the moderately disease-endemic area.
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of a detailed cost-effectiveness analysis of a potential vaccine
against C. immitis.
Data and Methods
We used a decision model to evaluate the health and eco-
nomic consequences of withholding the vaccine, screening
and vaccinating only those susceptible to infection (screen-
ing/vaccination), or vaccinating all eligible persons. Taking a
societal perspective, we calculated the incremental cost-
effectiveness of these strategies (formula in Appendix I,
online; URL: http://www.cdc.gov/ncid/eid/vol7no5/barnato_
appendix1.htm), and we discounted both costs and benefits
at an annual rate of 3%. We performed one-way sensitivity
analyses on all the model variables, as well as a three-way
sensitivity analysis of the most sensitive variables, and best-
and worst-case scenarios.
We based the estimates for input variables on the litera-
ture whenever possible (Appendix II Table). Our base-case
estimates represent our judgment about the best estimate
from the literature and discussion with experts. The ranges
for costs represent variation by 25% above and below the
base-case estimate, except where otherwise specified. The
ranges for sensitivity analyses on quality-of-life estimates
represent the 25th and 75th percentiles of patients’ assess-
ments of quality of life (15), except where otherwise speci-
fied. The authors had complete scientific and editorial
independence from the funding agencies.
Decision Model
We developed a Markov model (Figure 2) with Decision
Maker software (version beta 0.99.11.14.0a, 2000, S. Pauker,
et al., Boston, MA) (16,17) to track hypothetical cohorts of
patients who either did not receive the C. immitis vaccine,
received it, or received it only if their skin test was negative.
Patients who received the vaccine were at risk for pain at the
injection site, mild to moderate fever, and anaphylaxis with-
out death. Vaccinated patients were at decreased risk for
extrapulmonary dissemination after primary infection.
Patients neither immune from previous infection nor suc-
cessfully vaccinated were at risk for C. immitis infection and
serious sequelae. All patients were at risk for dying from
other causes (18). We followed cohorts until death, with a
Markov cycle length of 1 month. 
Patient Population
We used epidemiologic and demographic data from two
California counties (Kern and Tulare) and eight Arizona
counties (Cochise, Gila, Graham, Maricopa, Pima, Pinal,
Santa Cruz, and Yavapai) as proxies for the population fea-
tures of highly endemic regions (2,19; Internal Revenue Ser-
vice, unpub. data). We used two cohorts representing the
weighted average age and prior probability of naturally
acquired immunity among children (ages <17) and adults
(ages 18 to 65) in 10 highly disease-endemic counties. New
residents with no natural immunity were added to these
cohorts. Children had an average age of 8.85 years, and
14.5% were naturally immune; adults had an average age of
39.51 years, and 47.5% were naturally immune.
Clinical Manifestations
Smith's classic studies in military recruits stationed in
disease-endemic regions during World War II established that
60% of infected persons have no symptoms and 40% have a
flulike illness (20). Asymptomatic infection and symptomatic
infection with recovery confer probable lifelong immunity
with a positive delayed-type hypersensitivity skin-test reac-
tion to coccidioidin or spherulin. However, a fraction of per-
Figure 2. Schematic representation of the decision model and deci-
sion model subtrees. The square node represents a decision to use
one of the three strategies: no vaccination, vaccination of susceptible
persons identified through a screening skin test, or vaccination of all
persons. Circles represent chance nodes. After a strategy is chosen,
the patient enters a Markov tree (denoted by a rectangle containing
circles connected by an arrow). The Markov tree represents clinical
events that can occur during each 1-month period as a patient is fol-
lowed until death. Subtrees show events that may occur to patients
during a 1-month cycle. Dissemination subtree: The site of extrapul-
monary dissemination can be to the brain (meningitis) or elsewhere
(e.g., bone). The outcome of dissemination can be death from other
causes, death from disseminated coccidioidomycosis, or survival. If
the patient survives, he or she can survive in a disabled or nondis-
abled state. Each month thereafter, the patient is at risk for relapse.
Chronic subtree: Each month a patient with chronic pulmonary coc-
cidioidomycosis can die from other causes, remain infected, die from
chronic pulmonary infection, or be cured and rendered immune.
Immune subtree: On any given month, a patient who is immune to
infection can die of other causes or remain alive and immune to coc-
cidioidomycosis.
*At risk for dissemination relapse.Synopses
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sons do not have simple self-limited disease and instead more
serious illness develops, such as respiratory failure, chronic
pneumonia, and extrapulmonary dissemination (20-23). We
present more clinical detail in Appendix I, online, only (at
URL:www.cdc.gov/eid/v7n5/barnato-appendix1.htm) and sum-
marize probability estimates, costs, and utilities in the Appen-
dix II Table. 
Vaccine and Skin-Test Characteristics 
Animal trials of the vaccine rely on intraperitoneal or
intranasal challenge with large loads of C. immitis. The out-
come measure is survival or death from disseminated dis-
ease. Because the mechanism of action of the putative
vaccine is not known, we conservatively assumed that vacci-
nation prevents extrapulmonary dissemination but not pri-
mary infection. We evaluated this assumption in a
sensitivity analysis.
We assumed that all vaccinated persons comply with 3
doses in 1 year and all develop an antibody response. We
assumed that the vaccine reduced the probability of dissemi-
nation by 75%, with lifelong duration, based on experience
with hepatitis B vaccine, a widely used subunit vaccine. We
examined the effects of compliance with each strategy and
the effect of waning immunity. 
Using data from hepatitis B vaccine as a proxy, we
assumed that 25% of patients would experience mild side
effects such as local arm pain, fever, and nausea and that 1
in 600,000 patients would experience nonfatal anaphylaxis
requiring hospitalization (24). 
For screening before vaccination, studies suggested a
sensitivity of 70% and a specificity of 90% for the spherulin
intradermal test (25-30).
Quality of Life
Our model included intermediate health states that may
be associated with decrements in quality of life. To adjust for
such decrements, we included quality adjustments in our
model (Appendix II Table). Because there are no quality-of-
life studies for coccidioidomycosis, we used proxy health
state utilities in published studies or clinical judgment. All
illness utilities were multiplied by age-specific “healthy” util-
ities to account for the age at which an illness was con-
tracted. We assumed that primary pulmonary infection
causes a substantial heath status decrement only in those
who are sick enough to be diagnosed. Among those with pri-
mary pulmonary disease that goes undiagnosed, we assigned
a health state utility equal to well for this illness episode,
but accounted for lost time from work due to illness (see
Costs, below). For the short-term vaccine side effects, we cap-
ture quality-of-life impact as a decrease in utility of one-
tenth of a quality-adjusted day. The base case and ranges for
these quality-of-life adjustments reflect our judgment about
the impact of these episodes on patients. We evaluated the
effects of these utility assumptions in sensitivity analyses.
Costs
Direct Medical Costs
All costs are presented in 2000 U.S. dollars (Appendix II
Table). For costs of inpatient care, we used cost-adjusted
charges from the 1996 Nationwide Inpatient Sample of the
Healthcare Cost and Utilization Project (31). For outpatient
services, we used the 2000 Medicare national physician fee
schedule (32). For outpatient services not listed in the Medi-
care fee schedule, we used reimbursement received by Kern
County service providers (R. Talbot, pers. comm.) We
assumed that patients severely disabled by coccidioidal men-
ingitis would require home support and used the average
payment per Medicare home health beneficiary as a proxy
for this cost (33).
Vaccine and Other Costs
In our base-case analysis, we assumed the cost of the
vaccine was $180. We chose this value for the base case
because it is the reimbursed fee for the three-shot hepatitis
B series, an existing subunit vaccine. We examined a broad
range of vaccine costs ($100 to $400) in sensitivity analyses.
For circumstances in which quality-of-life changes do
not capture the inconvenience of illness or medical care, we
included time costs, as noted in the online Appendix I. 
Results
Prevention of Illness and Death
We calculated the number of cases of disseminated dis-
ease and deaths per 100,000 persons that would be pre-
vented over the lifetime of each cohort if children and adults
were immunized, assuming rates of vaccine coverage of 40%,
60%, 80%, and 100% (Table 1). For example, if 60% of chil-
dren were vaccinated, 93 cases of dissemination, 64 cases of
disability, and 7 deaths would be averted and $2 million
saved per 100,000 population. If 60% of adults underwent
screening followed by vaccination, 38 cases of dissemination,
24 cases of disability, and 2 deaths would be prevented at a
cost of $5.4 million per 100,000 population. 
Table 1. Lifetime cases of dissemination, disability, and death prevented and costs per 100,000 population if children are vaccinated and adults 
are screened, then vaccinated
Dissemination
prevented
Disability
prevented
Deaths 
prevented
Net cost
($ millions)
Compliance Children Adults Children Adults Children Adults Children Adults
100% 154 63 106 39 12 4 -3.3 9
80% 124 50 85 32 10 3 -2.6 7.2
60% 93 38 64 24 7 2 -2 5.4
40% 62 25 42 16 5 2 -1.3 3.6Synopses
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Costs and Effectiveness
We calculated the effectiveness, costs, and cost-effective-
ness of each strategy in each population, expressed in Table
2 as the per-person cost and health benefit. Among children,
vaccination saved 1.9 quality-adjusted life days (QALD) and
$33 per person. Among adults, screening followed by vacci-
nation saved 0.5 QALD per person and cost $62,000 per
QALY gained over no vaccination. For adults, the incremen-
tal gain from vaccinating all persons compared with screen-
ing followed by vaccination contributed an additional 0.05
QALD at a cost of $235,000 per QALY gained.
Sensitivity Analyses
We performed one-way sensitivity analyses over the
ranges of all input variables listed in the table in Appendix
II and on critical assumptions, such as the vaccine mecha-
nism of action and target population. Among children, vacci-
nation was no longer cost-saving at the lowest ranges of
vaccine efficacy, infection rate, dissemination rate, long-term
care cost for severe disability, and medical follow-up cost
after nonmeningeal dissemination and chronic pulmonary
disease; the vaccine also was not cost-saving in children
when we used the highest ranges of vaccine cost, meningitis
mortality, emigration, and discount rate among children.
The counter-intuitive effect of meningitis deaths is due to the
decrease in survivors subject to long-term care costs from
post-meningitis disability. Among adults, sensitivity analy-
ses that changed the cost-effectiveness ratio by >$40,000 per
QALY gained included infection rate, vaccine effectiveness,
discount rate, vaccine cost, dissemination rate, emigration
rate, and office visit time. Only the vaccine cost changed the
preferred strategy among adults. Below $106 per 3 doses,
vaccination was preferred over screening/vaccination, with a
cost-effectiveness ratio of $30,000 per QALY gained. 
Vaccine Duration
Our base-case analysis assumed lifetime immunity after
vaccination, but vaccine protection may wane. If vaccine pro-
tection waned to zero in 15 years, vaccination saved 0.82
QALD per child and cost $47,300 per QALY gained, and
screening/vacccination saved 0.28 QALD per adult and cost
$165,500 per QALY gained.
Vaccine Mechanism of Action
If the vaccine prevented primary infection rather than
dissemination alone, vaccination saved 2.26 QALD and $46
per vaccinated child over no vaccination. Screening/vaccina-
tion saved 0.66 QALD per adult, costing $46,500 per QALY
saved.
Three-Way Sensitivity Analysis of Infection Rate, 
Vaccine Effectiveness, and Cost
Our base case assumed an infection rate of 2% per year,
vaccine effectiveness of 75%, and a vaccine cost of $180.
However, the vaccine may have some use in areas of lower
endemicity. Also, because the vaccine does not yet exist, its
cost and effectiveness are unknown. We present the effects of
varying costs and effectiveness of the vaccine under two con-
ditions: 0.5% infection rate per year and 2% per year (our
base case of highly endemic regions) (Figure 3). In our base
case for children, the $180 vaccine remains cost-saving down
to an effectiveness of 65% and costs <$50,000 per QALY until
vaccine effectiveness drops below 30%, confirming that the
vaccine need not be highly effective to be cost-effective in
Table 2. Health and economic outcomes of vaccination strategiesa
Age Strategy
b
Life 
expectancy 
(years; days)
Incremental 
life 
expectancyc 
(days)
Quality-
adjusted life 
expectancy
(years; days)
Incremental 
quality-
adjusted life 
expectancyc 
(days)
Cost
($)
Incremental
 costd
($)
CE ratio
($/QALY)
e
<17 No vaccine 28; 160.15 - 25; 172.98 - 35,196 - -
Screen/
vaccinate
28; 160.58 0.43 25; 174.66 1.68 35,187 -9 -
Vaccinate 28; 160.62 0.04 25; 174.84 0.18 35,163 -24 Dominates
18-
65
No vaccine 21; 272.68 - 18; 60.12 - 47,477 - -
Screen/
vaccinate
21; 272.82 0.14 18; 60.65 0.53 47,568 90 62,000
Vaccinate 21; 272.84 0.02 18; 60.70 0.05 47,601 33  235,000
aLife expectancy and costs are discounted at 3% per year.
bStrategies are ranked by effectiveness, from the least to the most effective, for each age group.
cAll incremental values compare an alternative with the next most effective strategy (e.g., cost [screen/vaccinate] – cost [no vaccine] = incremental cost [screen/
vaccinate over no vaccine]).
dNegative values reflect cost savings compared to the next most effective strategy.
eCost-effectiveness ratio: refer to online Appendix I for formula. A strategy dominates if it is both more effective and less expensive than all comparison
strategies. 
Screen/vaccinate = vaccination of susceptible persons identified through a screening skin test; vaccinate = vaccination of all p ersonsSynopses
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younger populations. A $400 vaccine costs approximately
$50,000 per QALY gained among children at 65% effective-
ness. A $400 vaccine would be economically unfavorable for
the screening/vaccination strategy in adults at an annual
infection rate of 2%, even at 90% vaccine effectiveness. At an
infection rate of 0.5% per year, as might be seen in southern
California (34), all strategies except $180 vaccination at 90%
effectiveness in children are economically unfavorable.
Discount Rate
Among children, vaccination saved 5.95 QALD and $563
over no vaccination when costs and benefits were not dis-
counted. At a discount rate of 5%, vaccination was no longer
cost-saving at $27,600 per QALY gained. For adults, chang-
ing the discount rate from 0% to 5% changed the cost-effec-
tiveness ratio of screening/vaccination compared with no
vaccination from $30,800 to $155,000 per QALY gained.
Dissemination Rate
Our base-case analysis used a dissemination rate of
0.38% based on the assumption that only blacks and Asians
had higher rates of dissemination than whites. We evaluated
a range of 0.25% to 0.55% to determine the effect of assum-
ing all non-whites (including Hispanics) had rates of dissem-
ination equal to that of whites (0.25%) or that of blacks
(3.4%). Among children, vaccination saved 2.71 QALD and
$143 per child vaccinated at an overall dissemination rate of
0.55%, and 1.22 QALD at a cost of $15,300 per QALY gained
at the 0.25% dissemination rate. Among adults, varying the
dissemination rate from 0.25% to 0.55% changed the cost-
effectiveness ratio of screening/vaccination over no vaccina-
tion from $25,400 to $125,000 per QALY gained.  
New Residents 
If one considers new residents separately, vaccination
saved 2.18 QALD and $75 per immigrant child vaccinated,
and saved 1.13 QALD per immigrant adult vaccinated, cost-
ing $13,500 per QALY gained.
We present best- and worst-case scenarios in Appendix I
(online). 
Discussion
We evaluated the usefulness of a potential vaccine
against C. immitis in highly disease-endemic regions. Vacci-
nation was cost-saving among children. A screening/vaccina-
tion strategy cost $62,000 per QALY gained among adults.
Although the increase in quality-adjusted life expectancy
from an immunization program is modest for one individual
patient, this aggregates to an important number of illnesses
and deaths prevented (Table 1). Furthermore, the life expect-
ancy gains are comparable with gains from other immuniza-
tions. Vaccination for coccidioidomycosis (universally among
children and after screening in adults) saved 0.14 to 0.47 life
days and 0.53 to 1.86 QALD per person over no vaccination.
In comparison, vaccination against pneumococcal bactere-
mia among elderly people saves 1.2 QALD per person vacci-
nated (35); infant vaccinations against measles, mumps,
rubella, and pertussis each save 2.7, 3, 0.3, and 3.3 life days,
respectively (36). To further place benefits in perspective, if
the birth cohort in highly endemic counties of California and
Arizona were immunized in 2001, 11 deaths would be
averted and $3 million would be saved (in net present value)
over the lifetime of these children. 
The only previous analysis of the cost-effectiveness of a
vaccine against coccidioidomycosis drew different conclu-
sions. An IOM report considered the costs and benefits of
research and development into a vaccine for C. immitis and
found that the immunization of infants in endemic regions
and immigrants of any age would cost >$100,000 per QALY
(14). Our analysis evaluated a different question: If a vaccine
were currently available, would it be cost-effective to immu-
nize people in highly endemic regions? Although the IOM
report acknowledged that the committee used rough esti-
mates and a simplified model, the primary reason that it
reached a different conclusion was that the cost of vaccine
development was included in the IOM model. Vaccine devel-
opment costs will influence the sale price of the vaccine.
Project directors of the Valley Fever Vaccine Project estimate
that research and development through phase III clinical tri-
als, supported largely by public and private philanthropic
sources, will cost $28 million (G. Rutherford, pers. comm.).
This figure is 10 times lower than that used by the IOM in
its analysis. To recoup $28 million over 5 years by immuniz-
ing 60% of the 90,000 annual birth cohort in highly endemic
regions of California and Arizona, the vaccine would have to
Figure 3. Sensitivity to infection rate, vaccine cost, and vaccine
effectiveness. The vaccine is less cost-effective at higher vaccine
cost, lower vaccine effectiveness and lower annual infection rates.
When the line crosses the x-axis, the strategy is cost-saving. QALY =
quality-adjusted life year; screen/vaccinate = vaccination of suscepti-
ble persons identified through a screening skin test; vaccinate = vac-
cination of all persons.Synopses
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be priced at $100 per vaccinated person. This is less than the
$180 vaccine cost assumed in our base-case analysis.
Sensitivity analyses found that the vaccine would be
cost-effective in children under assumptions of waning
immunity and would be even more effective and cost-saving
in children and cost-effective in adults if the vaccine pre-
vented primary infection. In highly endemic regions, vacci-
nation of children is cost-effective even at relatively low
levels of vaccine effectiveness if the vaccine is priced at $180.
A $180 vaccine had to be >85% effective for screening/vacci-
nation to cost <$50,000 per QALY in adults. Paradoxically,
an even higher annual infection rate would make a screen-
ing/vaccination strategy less favorable in adults because
most of them would have already acquired natural immunity
by age 40. At an annual infection rate one-fourth of that seen
in the Central Valley of California, such as might be seen in
southern California, the only cost-effective strategy would be
to immunize children with an inexpensive and highly effica-
cious vaccine. If dissemination rates are higher than our
base case, as might be seen in the elderly and those with
chronic diseases, screening/vacccination becomes cost-effec-
tive for adults. 
The vaccine is much more effective in persons without
naturally acquired immunity. A vaccination strategy that
targeted new residents in highly endemic regions would
exploit easily obtainable risk factor information. However,
such a policy might be unacceptable to members of the popu-
lation excluded by such a strategy. Finally, because vaccina-
tion is a preventive intervention that can take years before
accruing a health benefit (in contrast to acute health-care
interventions), our results were highly sensitive to discount
rate. 
Our model has limitations. The ecology of endemic
regions has changed substantially with urbanization since
Smith’s study in the 1940s (20). Furthermore, his studies
documenting infection and dissemination were conducted in
the military, which may not be representative of general pop-
ulation exposures. Our base-case analysis used the demo-
graphics in highly endemic areas to estimate a composite
dissemination rate for a multiracial population. We did not
model race independently, nor did we model exposure risk.
Workers with high levels of dust exposure may have higher
rates of infection and more to gain from early immunization. 
Our model assumed that all age groups without prior
immunity were at equal risk for adverse health outcomes
and had identical health-care costs. However, illness severity
and costs may be higher among the elderly. Reported cases of
coccidioidomycosis during Arizona’s 1991 to 1995 epidemic
occurred disproportionately among older adults (11). The
study did not discern whether this was due to reporting dif-
ferences, immune-suppressing coexisting conditions, a pre-
ponderance of new immigrants with higher risk for infection,
or an independent age-related phenomenon. The death rate
from primary pulmonary infection is as high as 26.8% among
persons over 65 (37), much higher than our composite base-
case estimate of 0.5%. The Kern County data on which we
based our cost assumptions revealed that hospitalization,
the greatest health-care expenditure associated with acute
illness, was 4.2 times more likely among people >50 years
old. Thus, we may have underestimated the potential effec-
tiveness and cost savings of the vaccine among older adults. 
Finally, our analysis did not model the effects of an
immunization program in immunocompromised patients.
Persons with compromised cell-mediated immunity, includ-
ing those with AIDS, malignancy, or therapeutic medical
immunosuppression, have higher rates of serious illness.
Many of these patients may have reactivation of previous
infection; it is unclear whether vaccination would be useful
in this clinical scenario. This is an area for future research
as results from clinical trials become available.
An uncommon disease in a national context, coccidioido-
mycosis has substantial ramifications for several regions
where epidemics have produced reported annual case rates
as high as 15 per 100,000 and substantial economic impact.
Diseases affecting <200,000 persons annually (orphan dis-
eases) require more incentives for research and develop-
ment. Our findings may contribute to the policy decisions for
vaccine development and distribution for C. immitis (39).
Our analysis suggests that a vaccine against  C. immitis
would have substantial public health benefit. An update of
this cost-effectiveness analysis can be performed when the
results of human vaccine trials become available.
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Appendix I. Clinical and Economic Background
Appendix I is online only; it contains the formula used to calcu-
late the incremental cost-effectiveness of these strategies; URL:
http://www.cdc.gov/ncid/eid/vol7/no5/barnato_appendix1.htmSynopses
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Appendix II Table. Input variables, quality of data, and sourcesa
Input variable Base-case estimate (range) Quality of evidenceb Source
Epidemiology (%)
Vaccine effectiveness  75 (20-90) I 2
Skin-test sensitivity  70 (50-80) II-2 3-5 
Skin-test specificity  90 (70-97) II-2 4,6,7 
Annual infection rate  2 (0.25-3) II-3 5,8-16 
Annual emigration among vaccinees out of highly endemic region 0.5 (0-4.2) II-2, III c
Symptomatic primary pulmonary disease after infection     40  II-2 18
Diagnosed symptomatic primary pulmonary disease  10 (5-15) III d
Death from primary pulmonary disease, given diagnosis      0.5 (0-26) II-2 19-22
Chronic pulmonary disease after diagnosed primary infection       5 (1-10) III 23-26
Death from chronic pulmonary disease      5 (0-20) III 24 e
Dissemination after infection    0.38(0.25-0.55) II-2 17
Meningitis, given dissemination  33 (23-44) II-2 21,26 
Death from meningeal dissemination 7 (5-40) II-2, III 27d,e
Moderate disability after meningeal dissemination 50 (40-60) III 27d,e
Severe disability after meningeal dissemination 17 (10-30) III 27d,e
Annual meningeal dissemination relapse rate, on treatment 2 (0-5) I, II-2 28-30
Death from nonmeningeal dissemination 2 (0-10) III e
Moderate disability after nonmeningeal dissemination 33 (20-50) III d,e
Annual nonmeningeal dissemination relapse rate 
    On treatment
  
2 (0-5) I, II-2, III 4c
    Off treatment 50 (35-65) I, II-2, III 31-34c
Mild vaccine side effects  25 (10-40) II-2 35
Vaccine anaphylaxis, x 10-4 1.67 (0.1-10) II-2 35
Direct medical costs ($)
  Three doses of vaccine   180 (100-400) III 36,37
  Skin test   12 (9-15) III 38 
  Home care, per month   2,450 (1,840-3,060) II-2 39
Diagnosed pulmonary disease   2,090 (1,570-2,610) II-2, III 40
Incident meningeal dissemination   9,510 (7,130-11,890) II-2 40
Medication and follow-up after Coccidioides immitis meningitis,f per 
month  
1,510 (1,130-1,890) II-2 41 e,g
Incident nonmeningeal dissemination 6,950 (5,210-8,690) II-2 40
Medication and follow-up for chronic pulmonary infection and 
nonmeningeal dissemination,f per month
530 (290-790) II-2 41 e,g
Inpatient vaccine anaphylaxis treatment   2,180 (1,640-2,730) II-2 40
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